European life sciences investment firm Sofinnova Partners has raised €725 million ($799 million) for its second crossover fund, exceeding its initial target as it seeks to provide growth capital to biotechnology and medical technology companies preparing to commercialize products and compete in global markets.
The fund, called Crossover II, is the largest ever raised by Sofinnova. It will focus primarily on European biotech and medtech businesses approaching commercialization or considering public listings, with selective investments in the United States and other markets.
The fundraising comes as Europe’s pharmaceutical industry presses governments to increase investment in medicines, accelerate clinical trials and improve policies aimed at keeping the region competitive with the United States and China. At the same time, governments facing budget constraints are under pressure to manage the cost of innovative treatments.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Sofinnova’s challenge is not a shortage of scientific research or promising companies, but the availability of capital to finance their expansion beyond the early stages of development.
“Europe has outstanding science and companies,” Kinam Hong, a partner at Sofinnova, told Reuters in an interview.
“It doesn’t have an innovation gap, but it really has a financing growth capital problem,” he said.
A crossover fund typically invests in private companies that are approaching commercialization or a potential stock market listing. It occupies a position between traditional venture capital, which often finances early-stage businesses, and public-market investment, providing companies with capital as they move towards larger-scale operations.
Sofinnova expects Crossover II to support about 15 companies. It has already invested in Hemab Therapeutics, a biotechnology company developing treatments for rare diseases; CellCentric, which is developing a treatment for multiple myeloma; and Neurent Medical, a medical device company focused on chronic rhinitis.
Hong said the firm intends to take an active role in its portfolio companies, helping them strengthen management teams, advance clinical trials and prepare for public listings.
The investment strategy also places emphasis on building businesses capable of operating independently over the long term, rather than relying on acquisitions as their primary route to growth.
The aim, Hong said, is to build companies for “successful longevity” even without mergers and acquisitions.
European Biotech Faces a Growth Financing Challenge
The fund’s launch comes amid concerns that European biotechnology companies struggle to secure the larger investments required to take promising treatments and medical technologies from development into commercial markets.
Europe has established research institutions, scientific talent and biotechnology businesses, but companies can face difficulties obtaining sufficient financing as they progress towards late-stage clinical trials, regulatory approvals and commercial expansion.
That funding gap can leave promising businesses dependent on overseas investors, partnerships or acquisitions to finance their next phase of development. It can also make it harder for European companies to retain control as they scale operations and compete internationally.
Crossover investment is designed to address part of that challenge by providing capital to companies that have moved beyond the earliest stages of development but are not yet fully established public businesses.
The pressure is considered relevant to the pharmaceutical sector, where lengthy clinical trials, regulatory requirements and commercial infrastructure can require substantial funding before a product generates meaningful revenue.
Drugmakers have called on European governments to improve the conditions for pharmaceutical innovation, including increasing spending on medicines and speeding up clinical development. However, public finances remain constrained, creating difficult choices over how governments fund access to new treatments.
Sofinnova’s strategy targets companies at the point where additional financing can support the transition from scientific development to commercial operations.
Crossover II builds on the firm’s earlier investment experience. Sofinnova’s first crossover fund backed Amolyt Pharma, a biotechnology company developing treatments for rare hormone disorders that was subsequently acquired by AstraZeneca.
It also invested in French biotechnology company Abivax, which is developing a treatment for ulcerative colitis.
Those investments underpin the range of outcomes available to crossover investors, from acquisitions by established pharmaceutical companies to the development of independent businesses seeking access to public markets.
With its second fund, Sofinnova plans to apply a similar approach across a portfolio of approximately 15 companies, concentrating on businesses with products or technologies approaching commercialization.
The €725 million raise also expands the firm’s capacity to support companies through capital-intensive stages of development, when financing requirements can rise substantially as clinical programmes advance and commercial preparations begin.
Sofinnova manages more than €4 billion ($4.4 billion) in assets across healthcare and sustainability investments. Its latest fund positions it to play a larger role in financing European life sciences companies seeking to move from promising research to commercially viable businesses.



